#arrivent biopharma

Newtown Square Biotech Loses Nearly Half Its Value After Lung Cancer Drug Fails Key Test

Shares of ArriVent BioPharma crashed about 47 percent to roughly $12 after its lead lung cancer drug failed the main goal of a Phase…